EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
168 hedge funds and large institutions have $617M invested in Eagle Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 59 increasing their positions, 61 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less capital invested
Capital invested by funds: $ → $
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
78% less call options, than puts
Call options by funds: $795K | Put options by funds: $3.59M
Holders
168
Holding in Top 10
1
Calls
$795K
Puts
$3.59M
Top Buyers
| 1 | +$11.8M | |
| 2 | +$9.35M | |
| 3 | +$8.7M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.49M |
| 5 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$6.69M |
Top Sellers
| 1 | -$39.8M | |
| 2 | -$6.29M | |
| 3 | -$4.28M | |
| 4 |
MCM
Matarin Capital Management
New York
|
-$3.76M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$3.08M |